AC
Avinash Chandrashekariah
About Avinash Chandrashekariah
Data last updated:
Avinash Chandrashekariah has 4 years in corporate governance. Holds Managing Director role. Currently with 2 companies, including Spyblood Healthcare Private Limited and Plotnew Bio Innovations Private Limited. Formerly with 1 company, such as Whimper Pharmalabs Private Limited. Engaged in Healthcare, General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
 Spyblood Healthcare Private Limited U73200TG2021PTC157421 | Managing Director | 29 Nov 2021 | 2021 | Active |
 Plotnew Bio Innovations Private Limited U74999KA2022PTC156248 | Managing Director | 04 Jan 2022 | 2022 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Whimper Pharmalabs Private Limited U21001KA2023PTC176584 | Director | 27 Jul 2023 | 2023 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Avinash Chandrashekariah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avinash Chandrashekariah
Avinash Chandrashekariah has 4 years in corporate governance. Holds Managing Director role. Currently with 2 companies, including Spyblood Healthcare Private Limited and Plotnew Bio Innovations Private Limited. Formerly with 1 company, such as Whimper Pharmalabs Private Limited. Engaged in Healthcare, General Business. Contributes to corporate operations.
Avinash Chandrashekariah is associated with 2 companies as Managing Director.
Avinash Chandrashekariah has expertise in Healthcare, General Business.
Avinash Chandrashekariah has 4 years in corporate governance.